Hodgkin lymphoma, version 2.2015.
Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.
Duke Scholars
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Recurrence
- Prognosis
- Positron-Emission Tomography
- Oncology & Carcinogenesis
- Neoplasm Staging
- Humans
- Hodgkin Disease
- Follow-Up Studies
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Recurrence
- Prognosis
- Positron-Emission Tomography
- Oncology & Carcinogenesis
- Neoplasm Staging
- Humans
- Hodgkin Disease
- Follow-Up Studies
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis